- Conditions
- Gastroesophageal Reflux Disease, Hiatal Hernia
- Interventions
- TIF Transoral Fundoplication, Sham placebo procedure
- Device · Other
- Lead sponsor
- EndoGastric Solutions
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Englewood, Colorado • Chicago, Illinois + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 29
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Gastroesophageal Reflux, Esophagitis
- Interventions
- Pantoprazole for approximately 9 weeks
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 9
- States / cities
- Anaheim, California • Los Angeles, California • Orange, California + 4 more
- Conditions
- Gastroesophageal Reflux Disease (GERD), Eosinophilic Esophagitis (EoE), Functional Dyspepsia
- Interventions
- Standard of Care esophagogastroduodenoscopy (EGD) with measurement of mucosal impedance
- Diagnostic Test
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Interventions
- CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
- Drug
- Lead sponsor
- Cogentus Pharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 247
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
- Conditions
- Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
- Interventions
- Cessation of Acid Suppressing Medications
- Other
- Lead sponsor
- Dallas VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Voice Disorders, Gastroesophageal Reflux
- Interventions
- Neuromuscular Electrical Stimulation, Unstimulated
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Esophagitis, Inflammation, Gastritis, Abdominal Pain, Heartburn
- Interventions
- Not listed
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Gastroesophageal Reflux
- Interventions
- Dexlansoprazole
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 1 Year to 11 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Anaheim, California • Miami Garden, Florida • Kansas City, Missouri + 1 more
- Conditions
- Erosive Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
- Interventions
- esomeprazole magnesium (oral medication)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 39
- States / cities
- Alabaster, Alabama • Anaheim, California • Dinuba, California + 36 more
- Conditions
- Esophagus Cancer, Esophageal Cancer Stage, Esophageal Cancer, Esophageal Neoplasms, Esophagus Adenocarcinoma, Esophagus, Barrett, Barrett Esophagus, Barrett Adenocarcinoma, Barrett Epithelium, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia, Barretts Esophagus With High Grade Dysplasia, Barretts Esophagus With Low Grade Dysplasia, Barrett Esophagus, Long-Segment, Barrett's Esophagus With Dysplasia, Unspecified, Barrett's Esophagus With Esophagitis, Gastroesophageal Reflux, Reflux Disease, Esophageal Adenocarcinoma, Esophageal Dysplasia, Esophageal Neoplasms Malignant
- Interventions
- EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)
- Diagnostic Test
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 658 participants
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- GERD, Gastroesophageal Reflux
- Interventions
- Prevacid Solutabs, Antireflux surgery
- Drug · Procedure
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- GERD
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Gerd, Eosinophilic Esophagitis
- Interventions
- MuVI Esophageal mucosal impedance testing
- Device
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Gastroesophageal Reflux Disease With Esophagitis
- Interventions
- CYP2C19 based dosing Proton Pump Inhibitors, Conventional proton pump inhibitor dose
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Digestive System Disorder, Dyspepsia, Esophagitis, Gastroesophageal Reflux Disease, Gastroparesis, Heartburn, Nausea and Vomiting
- Interventions
- Domperidone, Questionnaire Administration
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-erosive Reflux Disease, Erosive Esophagitis
- Interventions
- BLI5100
- Drug
- Lead sponsor
- Braintree Laboratories
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 60
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 48 more
- Conditions
- Erosive Esophagitis
- Interventions
- Nexium 20mg, Nexium 10mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 1 Year to 11 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 11
- States / cities
- Mobile, Alabama • Sacramento, California • Miami, Florida + 7 more
- Conditions
- Gastroesophageal Reflux Disease (GERD), Heartburn, Indigestion
- Interventions
- Secretol, Nexium
- Drug
- Lead sponsor
- Effexus Pharmaceutical
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Erosive Esophagitis
- Interventions
- Omeprazole/sodium bicarbonate
- Drug
- Lead sponsor
- Yvonne Romero
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Achalasia, Esophageal, GERD (Gastroesophageal Reflux Disease)
- Interventions
- Conventional POEM, Sling Fiber-Preserving POEM
- Procedure
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Erosive Esophagitis
- Interventions
- X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy
- Drug
- Lead sponsor
- Cinclus Pharma Holding AB
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Esophageal Adenocarcinoma, Barrett's Esophagus, Reflux Esophagitis
- Interventions
- Chlorhexidine gluconate
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Gastroesophageal Reflux Disease, Eosinophilic Esophagitis
- Interventions
- Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
- Drug
- Lead sponsor
- Dallas VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Dysphagia, Dysplasia, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophagitis, Gastroesophageal Reflux Disease, High Grade Dysplasia in Barrett Esophagus, Weight Loss
- Interventions
- Cytology Specimen Collection Procedure, Esophagogastroduodenoscopy, Laboratory Biomarker Analysis
- Other · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Portland, Oregon